Genedrive (GDR) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Aug 2024 10:39 AM
RNS
Director/PDMR Shareholding
12 Aug 2024 07:00 AM
RNS
First UK commercial sales of the CYP2C19-ID Kit
06 Aug 2024 07:00 AM
RNS
Directorate Change
31 Jul 2024 07:00 AM
RNS
NICE recommends CYP2C19-ID Kit in final guidance
15 Jul 2024 07:00 AM
RNS
Breakthrough Device Designation from the U.S. FDA
27 Jun 2024 09:28 AM
RNS
Short extension to NICE publication date
25 Jun 2024 07:00 AM
RNS
Holding(s) in Company
24 Jun 2024 11:13 AM
RNS
Holding(s) in Company
24 Jun 2024 11:12 AM
RNS
Holding(s) in Company
24 Jun 2024 11:11 AM
RNS
Holding(s) in Company
17 Jun 2024 04:41 PM
RNS
Holding(s) in Company
13 Jun 2024 03:22 PM
RNS
Holding(s) in Company
11 Jun 2024 12:54 PM
RNS
Holding(s) in Company
07 Jun 2024 11:00 AM
RNS
Holding(s) in Company
05 Jun 2024 03:45 PM
RNS
Holding(s) in Company
05 Jun 2024 11:39 AM
RNS
Holding(s) in Company
31 May 2024 03:56 PM
RNS
Block listing returns
31 May 2024 11:24 AM
RNS
Result of General Meeting
30 May 2024 07:00 AM
RNS
Result of Open Offer and REX Offer
24 May 2024 07:00 AM
RNS
Initial orders of the Genedrive MT-RNR1 Products
21 May 2024 11:00 AM
RNS
Key CYP2C19-ID test performance milestone achieved
15 May 2024 07:00 AM
RNS
Amendment to Open Offer timetable
14 May 2024 07:00 AM
RNS
Publication of Circular and Notice of GM
10 May 2024 07:00 AM
RNS
Completion of placing
09 May 2024 04:49 PM
RNS
Proposed REX Retail Offer
09 May 2024 04:48 PM
RNS
Proposed Fundraise for a minimum of £6.0 million
24 Apr 2024 03:36 PM
RNS
Clinical Trial Agreement
03 Apr 2024 05:00 PM
RNS
Application for Listing & Total Voting Rights
03 Apr 2024 07:00 AM
RNS
NICE recommends the Genedrive CYP2C19-ID Kit
28 Mar 2024 07:00 AM
RNS
Half-year Report
26 Mar 2024 07:00 AM
RNS
Investor presentation
19 Mar 2024 03:53 PM
RNS
Application for Listing & Total Voting Rights
15 Mar 2024 12:30 PM
RNS
Receipt of R&D tax credit
19 Feb 2024 07:00 AM
RNS
NICE Early Value Assessment update
06 Feb 2024 02:03 PM
RNS
Director/PDMR Shareholding
02 Feb 2024 03:35 PM
RNS
Total Voting Rights
19 Jan 2024 04:14 PM
RNS
Total Voting Rights
15 Jan 2024 03:21 PM
RNS
Total Voting Rights
10 Jan 2024 07:00 AM
RNS
Total Voting Rights
02 Jan 2024 07:00 AM
RNS
Equity Prepayment Facility drawdown
29 Dec 2023 11:44 AM
RNS
Result of AGM
20 Dec 2023 04:57 PM
RNS
Total Voting Rights
20 Dec 2023 07:00 AM
RNS
Initial overseas orders of MT-RNR1 ID kit
07 Dec 2023 07:00 AM
RNS
Total Voting Rights
06 Dec 2023 07:00 AM
RNS
Posting of annual report and notice of AGM
06 Dec 2023 07:00 AM
RNS
Total Voting Rights
04 Dec 2023 01:13 PM
RNS
MT-RNR1 ID kit adopted for routine use in Brighton
30 Nov 2023 05:29 PM
RNS
Block listing Interim Review
30 Nov 2023 07:00 AM
RNS
Final Results
29 Nov 2023 05:25 PM
RNS
Equity Prepayment Facility drawdown

Genedrive plc is a medical equipment company based in Manchester, UK that develops and sells point-of-care molecular diagnostic platforms. Their products are used in healthcare settings, particularly in emergency medicine, for patient stratification and disease detection. Genedrive's goal is to improve clinical outcomes with easy-to-use tests. 

 Genedrive's major products include:
Genedrive CYP2C19 ID Kit: A rapid test that establishes metaboliser status in time-critical settings
Genedrive MT-RNR1 ID Kit: The world's first point-of-care genetic test to reduce the risk of aminoglycoside induced hearing loss

Genedrive was founded on contract research services for pharmaceutical and biotech companies, and was originally named Epistem Holdings Inc. when it was floated on the London AIM market in 2007. The company was renamed genedrive plc in 2016 to reflect its new focus on molecular diagnostics, and divested its contract research services divisions in 2018.

GDR share price launched at 129p in 2007. 

UK 100

Latest directors dealings